Tang Aoxing, Zhu Meng, Zhu Jie, Zhang Da, Zhu Shiqiang, Meng Chunchun, Li Chuanfeng, Liu Guangqing
Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, PR China.
Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, PR China.
Vaccine. 2024 Dec 2;42(26):126468. doi: 10.1016/j.vaccine.2024.126468. Epub 2024 Oct 29.
Feline herpesvirus type 1 (FHV) and feline calicivirus (FCV) are significant pathogens causing upper respiratory tract disease in cats. Existing inactivated or modified live vaccines against FCV and FHV face limitations in safety and efficacy. To overcome these challenges, a recombinant strain FHV ΔgI/gE-FCV VP1 was developed by deleting the gI/gE gene and concurrently expressing FCV VP1, using the FHV WX19 strain as the parental virus. Results indicated the presence of FCV VP1 in FHV ΔgI/gE-FCV VP1-infected CRFK cells, confirmed through protein blotting and immunofluorescence assays and virus-like particles (VLPs) of FCV were observed using transmission electron microscopy. For efficacy in cats, each animal received intranasal vaccination with 1 mL of FHV ΔgI/gE-FCV VP1 at 10 TCID. Following completion of vaccination on day 28, animals were exposed to a potent FCV strain. Assessments included clinical signs, nasal shedding, virus neutralizing antibodies, cytokine expression and postmortem histological testing. All vaccinations with FHV ΔgI/gE-FCV VP1 were deemed safe, with significantly reduced clinical disease scores, pathological changes and viral nasal shedding following infection and robust immune responses were induced. These findings collectively suggest the effectiveness of FHV-based recombinant vaccines in preventing FCV infections.
猫疱疹病毒1型（FHV）和猫杯状病毒（FCV）是引起猫上呼吸道疾病的重要病原体。现有的针对FCV和FHV的灭活疫苗或改良活疫苗在安全性和有效性方面存在局限性。为了克服这些挑战，以FHV WX19株为亲本病毒，通过删除gI/gE基因并同时表达FCV VP1，构建了重组毒株FHV ΔgI/gE-FCV VP1。结果表明，在FHV ΔgI/gE-FCV VP1感染的CRFK细胞中存在FCV VP1，通过蛋白质印迹和免疫荧光分析得到证实，并且使用透射电子显微镜观察到了FCV的病毒样颗粒（VLP）。为了评估对猫的有效性，每只动物鼻内接种1 mL含10个组织培养感染剂量（TCID）的FHV ΔgI/gE-FCV VP1。在第28天完成疫苗接种后，让动物接触一种强毒FCV毒株。评估包括临床症状、鼻腔排毒、病毒中和抗体、细胞因子表达和死后组织学检测。所有接种FHV ΔgI/gE-FCV VP1的疫苗均被认为是安全的，感染后临床疾病评分、病理变化和病毒鼻腔排毒显著降低，并且诱导了强烈的免疫反应。这些发现共同表明基于FHV的重组疫苗在预防FCV感染方面的有效性。
